methyl 2-(4-chlorophenyl)imidazo[1,2-a]pyridine-6-carboxylate | 907945-78-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 2-(4-chlorophenyl)imidazo[1,2-a]pyridine-6-carboxylate
• 英文别名: 2-(4-chloro-phenyl)-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester
• CAS: 907945-78-2
• 化学式: C₁₅H₁₁ClN₂O₂
• 分子量: 286.718
• InChiKey: KLEIZLSURQBLPH-UHFFFAOYSA-N

物化性质

• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-chlorophenyl)imidazo[1,2-a]pyridine-6-carboxylate 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 0.25h， 生成 2-(4-chlorophenyl)imidazo[1,2-a]pyridine-6-carboxylic acid
  参考文献：
  名称：

  EP1849465

  摘要：

  公开号：
• 作为产物：
  描述：

  6-氨基烟酸甲酯 、 2'-溴-4-氯苯乙酮 在 碳酸氢钠 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 40.0h， 生成 methyl 2-(4-chlorophenyl)imidazo[1,2-a]pyridine-6-carboxylate
  参考文献：
  名称：

  EP1849465

  摘要：

  公开号：

文献信息

• Imidazo[1,2-a]pyridines and their use as pharmaceuticals
  申请人：sanofi-aventis

  公开号：EP1964840A1

  公开（公告）日：2008-09-03

  Imidazo[1,2-a]pyridines and their use as pharmaceuticals The present invention relates to derivatives of imidazo[1,2-a]pyridines of the formula (I), in which R, R1 to R4 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  咪唑[1,2-a]吡啶及其作为药物的用途。本发明涉及咪唑[1,2-a]吡啶衍生物的公式(I)，其中R、R1至R4和n具有声明中指示的含义，这些衍生物调节内皮型一氧化氮(NO)合酶的转录，并且是有价值的药理活性化合物。具体来说，公式I的化合物上调内皮型NO合酶酶的表达，并可应用于需要增加该酶的表达或增加NO水平或正常化降低的NO水平的情况。该发明还涉及公式I化合物的制备方法，包括它们的药物组合物，以及公式I化合物用于制造刺激内皮型NO合酶表达或治疗各种疾病的药物，包括心血管疾病如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• Metal-free, efficient hydrazination of imidazo[1,2-a]pyridine with diethyl azodicarboxylate in neutral media
  作者：Yuanxiang Wang、Brendan Frett、Nick McConnell、Hong-yu Li

  DOI：10.1039/c4ob02284j

  日期：——

  The first example of metal-free regioselective hydrazination of imidazo[1,2-a]pyridine with diethyl azodicarboxylate is accomplished.

  第一个无金属的选择性取代咪唑[1,2-a]吡啶与双乙酰基叠氮甲酸乙酯的氢化反应已成功实现。
• IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS
  申请人：ZOLLER Gerhard

  公开号：US20100113412A1

  公开（公告）日：2010-05-06

  The present invention relates to derivatives of imidazo[1,2-a]pyridines of formula I, in which R, R1 to R4 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of formula I, to pharmaceutical compositions comprising them, and to the use of compounds of formula I for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的咪唑[1,2-a]吡啶衍生物，其中R、R1至R4和n具有所述权利要求中所示的含义，这些衍生物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，公式I的化合物上调内皮型NO合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备公式I的化合物的方法，包括它们的制药组合物，以及使用公式I的化合物刺激内皮型NO合酶的表达或治疗各种疾病，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏衰竭等。
• AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1849465A1

  公开（公告）日：2007-10-31

  The present invention provides a GPR receptor function regulator comprising the compound represented by the formula: [wherein ring A is an optionally substituted isocyclic or heterocyclic ring, P is a bond or spacer, ring D is an optionally substituted monocyclic aromatic ring which may be condensed with a 5-to 7-membered ring, V is a bond or the group represented by the formula -CR14=CR15 - or - N=CR16- (wherein R14, R15 and R16 each represents a hydrogen atom or optionally substituted hydrocarbon group), Q is a bond or spacer, and W is a carboxyl or a group biologically equivalent to a carboxyl] or its salt or a prodrug thereof

  本发明提供了一种 GPR 受体功能调节剂，包括由式表示的化合物： [其中环A是任选取代的异环或杂环，P是键或间隔物，环D是任选取代的单环芳香环，可与5-7元环缩合，V是键或由式-CR14＝CR15-或-N＝CR16-代表的基团（其中R14、R15 和 R16 各代表一个氢原子或任选取代的烃基），Q 是键或间隔物，W 是羧基或生物等价于羧基的基团]或其盐或其原药
• IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi-Aventis

  公开号：EP2129375A1

  公开（公告）日：2009-12-09